title: Evaluation of mesotherapeutic injections of three different combinations of lipolytic agents for body contouring.
abstract: BACKGROUND
  There has been significant interest recently in the technique of mesotherapy as a method of 'melting fat' for body contouring.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the safety, efficacy and lipolytic potential of several compounds commonly used in cosmetic mesotherapy.
  
  
  METHODS
  A total of 75 women (mean age: 33 years) were separated randomly into three mesotherapy groups. Injections were performed for 15 treatments once a week. The main component of each cocktail was phosphatidylcholine/deoxycholic acid for group 1, caffeine for group 2, and Conjonctyl® for group 3. Outcome was evaluated by weight, body fat percentage (BFP), circumference measurements, and patient questionnaires.
  
  
  RESULTS
  Seventy-two of all the patients (96%) showed a circumference loss. An average circumference reduction of 4.41 cm per site for group 1, 2.99 cm for group 2, and 2.10 cm for group 3 was achieved. Mean body circumference loss was statistically significant, with p < 0.00. Weight loss was 5.33 ± 1.09 kg for group 1, 3.74 ± 1.51 kg for group 2, and 2.82 ± 1.43 kg for group 3. Seventy-four subjects (98.7%) showed a BFP decrease. A questionnaire indicated high patient satisfaction (63%). No patient showed irregularities, dimples or any serious side effects after treatment.
  
  
  CONCLUSIONS
  Mesotherapy is a well-tolerated and effective alternative treatment modality for reducing the diameter of body circumference.
authors: Lazerart Clinics, Division of Dermatology, Istanbul, Turkey. zekayikutlubay@hotmail.com
authors: Zekayi
authors: Z
authors: Kutlubay
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects*; D000328:Adult; D001835:Body Weight; D002110:Caffeine / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D035002:Lower Extremity / Q000033:anatomy & histology*; D057748:Mesotherapy / Q000009:adverse effects*; D008875:Middle Aged; D009929:Organ Size; D017646:Organosilicon Compounds / Q000009:adverse effects / Q000627:therapeutic use; D017060:Patient Satisfaction; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use; D055105:Waist Circumference; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D017646:Organosilicon Compounds; D010713:Phosphatidylcholines; D012459:Salicylates; C568838:cellucare; C005152:lipostabil; C039272:conjonctyl; D002110:Caffeine; D006820:Hyaluronic Acid